person · Reporting owner

Topper James N

Disclosed activity across 16 companies

Tapewire entity: 26591
SEC CIK: 0001341382

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ANAPTYSBIO, INCANAB · Entity 4640	Director · 10% owner	January 06, 2023	January 11, 2023
Allena Pharmaceuticals, Inc.ALNA · Entity 130904	Director · 10% owner	November 17, 2020	November 18, 2020
Aptinyx Inc.APTX · Entity 120922	Director	March 31, 2020	April 02, 2020
Attovia Therapeutics, Inc.ATTO · Entity 4984	Director	August 04, 2026	August 04, 2026
Frazier Lifesciences Acquisition CorpFLAC · Entity 122080	Director · Chief Executive Officer	December 08, 2020	December 17, 2020
MBX Biosciences, Inc.MBX · Entity 4247	10% owner	September 26, 2025	September 30, 2025
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	10% owner	July 22, 2019	July 24, 2019
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	September 15, 2025	September 17, 2025
Passage BIO, Inc.PASG · Entity 7829	10% owner	March 03, 2020	March 03, 2020
Phathom Pharmaceuticals, Inc.PHAT · Entity 5177	Director · 10% owner	May 19, 2026	May 21, 2026
Sierra Oncology, Inc.SRRA · Entity 125698	Director · 10% owner	February 14, 2017	February 16, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANAPTYSBIO, INC

Report date January 06, 2023 · Filed January 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.23 · Expires 2033-01-05	Direct	10,600	Reported balance After 2023-01-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-06 · Grant · Acquired 10,600 · Balance 10,600 F1: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	3,900	Reported balance After 2023-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-06 · Grant · Acquired 3,900 · Balance 3,900 F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Allena Pharmaceuticals, Inc.

Report date November 17, 2020 · Filed November 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2030-11-16	Direct	14,000	Reported balance After 2020-11-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-11-17 · Grant · Acquired 14,000 · Balance 14,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Aptinyx Inc.

Report date March 31, 2020 · Filed April 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,195,055	Reported balance After 2020-03-31 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-03-31 · Grant · Acquired 4,976 · Balance 3,195,055 F1: The shares were issued to the Reporting Person, who elected to take unrestricted shares in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of shares issued was determined by dividing the cash compensation otherwise payable with respect to the quarter by the price of a share on the date of the grant. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the Reporting Person, who elected to take unrestricted shares in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of shares issued was determined by dividing the cash compensation otherwise payable with respect to the quarter by the price of a share on the date of the grant.

F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.

Attovia Therapeutics, Inc.

Report date August 04, 2026 · Filed August 04, 2026

This filing explicitly reported no securities owned.

Frazier Lifesciences Acquisition Corp

Report date December 08, 2020 · Filed December 17, 2020 · Amendment

Jointly reported with Frazier Lifesciences Sponsor LLC, Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Heron Patrick J

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-12-08 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement. F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer. F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement.

F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer.

F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein.

MBX Biosciences, Inc.

Report date September 26, 2025 · Filed September 30, 2025

Jointly reported with Heron Patrick J, FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences X, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	5,219,440	Reported balance After 2025-09-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-26 · Purchase · Acquired 666,666 · Balance 5,219,440 F1: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Mirum Pharmaceuticals, Inc.

Report date July 22, 2019 · Filed July 24, 2019

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,566,912	Last balance in matching sequence After 2019-07-22 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2019-07-22 · Conversion · Acquired 3,116,912 · Balance 3,116,912 F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2019-07-22 · Purchase · Acquired 450,000 · Balance 3,566,912 F3: The shares were purchased in the Issuer's initial public offering. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-07-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-22 · Conversion · Disposed 24,935,300 · Balance 0 F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

F3: The shares were purchased in the Issuer's initial public offering.

NewAmsterdam Pharma Co N.V.

Report date September 15, 2025 · Filed September 17, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	3,028,524	Reported balance After 2025-09-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-09-15 · Purchase · Acquired 660 · Balance 3,028,524 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Frazier Lifesciences Sponsor LLC	3,801,000	Reported balance Holding disclosure · report date 2025-09-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,801,000 F3: The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Passage BIO, Inc.

Report date March 03, 2020 · Filed March 03, 2020

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,009,219	Last balance in matching sequence After 2020-03-03 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2020-03-03 · Conversion · Acquired 2,977,242 · Balance 2,977,242 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2020-03-03 · Conversion · Acquired 1,049,175 · Balance 4,026,417 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 3 · 2020-03-03 · Conversion · Acquired 432,802 · Balance 4,459,219 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 4 · 2020-03-03 · Purchase · Acquired 550,000 · Balance 5,009,219 F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-03-03 · Conversion · Disposed 2,977,242 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-03-03 · Conversion · Disposed 1,049,175 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-03-03 · Conversion · Disposed 432,802 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Phathom Pharmaceuticals, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	66,718	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 66,718 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	59,403	Reported balance Holding disclosure · report date 2026-05-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 59,403 F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences IX, L.P.	5,827,415	Reported balance Holding disclosure · report date 2026-05-19 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,827,415 F3: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy FHMLS IX, L.L.C.	1	Reported balance Holding disclosure · report date 2026-05-19 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1 F4: The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Topper Group III LLC	3,912	Reported balance Holding disclosure · report date 2026-05-19 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 3,912 F5: The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F4: The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F5: The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Sierra Oncology, Inc.

Report date February 14, 2017 · Filed February 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences VIII, L.P.	5,925,926	Reported balance After 2017-02-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-02-14 · Purchase · Acquired 5,925,926 · Balance 5,925,926 F1: The reporting person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLSIII"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FLSIII. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Healthcare VI, L.P.	2,186,195	Reported balance Holding disclosure · report date 2017-02-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,186,195 F2: The reporting person, Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are the managing members of FHM VI, LLC, which is the general partner of FHM VI, LP, which is the general partner of Frazier Healthcare VI, L.P. ("FHVI"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FHVI. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLSIII"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FLSIII. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F2: The reporting person, Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are the managing members of FHM VI, LLC, which is the general partner of FHM VI, LP, which is the general partner of Frazier Healthcare VI, L.P. ("FHVI"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FHVI. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALPINE IMMUNE SCIENCES, INC.

Report date May 18, 2024 · Filed May 21, 2024

Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences VIII, L.P.	Reported balance After 2024-05-18 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-05-18 · Other · Disposed 2,829,347 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01	Direct	Reported balance After 2024-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2029-01-01	Direct	Reported balance After 2024-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01	Direct	Reported balance After 2024-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2031-01-03	Direct	Reported balance After 2024-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-02	Direct	Reported balance After 2024-05-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02	Direct	Reported balance After 2024-05-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01	Direct	Reported balance After 2024-05-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F3: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any.

F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Arcutis Biotherapeutics, Inc.

Report date October 24, 2023 · Filed October 26, 2023

Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2023-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,764,232	Reported balance After 2023-10-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-24 · Purchase · Acquired 80,000 · Balance 8,764,232
Common StockSEC Table I · non-derivative	IndirectFHM Life Sciences VIII, L.L.C.	7	Reported balance Holding disclosure · report date 2023-10-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7 F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Topper Group II LLC	11,266	Reported balance Holding disclosure · report date 2023-10-24 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,266 F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.
Common StockSEC Table I · non-derivative	IndirectBy Topper Family Revocable Trust	19,381	Reported balance Holding disclosure · report date 2023-10-24 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 19,381 F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectBy The Heron Living Trust 11/30/2004	23,688	Reported balance Holding disclosure · report date 2023-10-24 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 23,688 F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
Common StockSEC Table I · non-derivative	IndirectBy Patrick J. Heron	8,687	Reported balance Holding disclosure · report date 2023-10-24 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 8,687 F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.

F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.

F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.

F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.

Entasis Therapeutics Holdings Inc.

Report date January 09, 2020 · Filed January 13, 2020

Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2020-01-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,299,953	Reported balance After 2020-01-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-01-09 · Sale · Disposed 50,000 · Balance 1,299,953 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4 F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4

F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

HilleVax, Inc.

Report date September 17, 2025 · Filed September 17, 2025

Jointly reported with Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	0	Reported balance After 2025-09-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-17 · Other · Disposed 8,535,337 · Balance 0 F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share. F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Patrick J. Heron	0	Reported balance After 2025-09-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-09-17 · Other · Disposed 17,199 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share.

F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Tarsus Pharmaceuticals, Inc.

Report date October 20, 2020 · Filed October 21, 2020

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2020-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,917,157	Last balance in matching sequence After 2020-10-20 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-10-20 · Conversion · Acquired 1,390,376 · Balance 1,390,376 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 2 · 2020-10-20 · Conversion · Acquired 214,281 · Balance 1,604,657 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 3 · 2020-10-20 · Purchase · Acquired 312,500 · Balance 1,917,157 F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-20 · Conversion · Disposed 1,390,376 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-20 · Conversion · Disposed 214,281 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2026 Filed May 21, 2026 20:30 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	24,122	$0.00	$0.00	Disclosure SEC source: 0001193125-26-234572 · ownership.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,718 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
September 26, 2025 Filed Sep 30, 2025 20:59 UTC	MBX Biosciences, Inc. MBX · Entity 4247	PurchaseCommon Stock	666,666	$18.00	$11,999,988.00	Disclosure SEC source: 0001231919-25-000267 · form4-09302025_080948.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 5,219,440 F1 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 17, 2025 Filed Sep 17, 2025 21:20 UTC	HilleVax, Inc. HLVX · Entity 75097	OtherCommon Stock	17,199	$1.95	$33,538.05	Disclosure SEC source: 0001790879-25-000007 · form4-09172025_090911.xml · nonDerivative · entry 2 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Patrick J. Heron Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. Read SEC document
September 17, 2025 Filed Sep 17, 2025 21:20 UTC	HilleVax, Inc. HLVX · Entity 75097	OtherCommon Stock	8,535,337	$1.95	$16,643,907.15	Disclosure SEC source: 0001790879-25-000007 · form4-09172025_090911.xml · nonDerivative · entry 1 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 0 F1 · price: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:22 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	660	$23.70	$15,638.90	Disclosure SEC source: 0001341382-25-000007 · form4-09172025_090930.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,028,524 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
September 08, 2025 Filed Sep 10, 2025 21:19 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	1,260	$24.99	$31,487.40	Disclosure SEC source: 0001415889-25-024111 · form4-09102025_090907.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,027,864 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.86 to $25.00. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
August 11, 2025 Filed Aug 13, 2025 20:49 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	471	$23.98	$11,293.97	Disclosure SEC source: 0001415889-25-021660 · form4-08132025_080851.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,026,604 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.91 to $24.00. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
June 25, 2025 Filed Jun 26, 2025 23:41 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	1,260	$18.26	$23,011.63	Disclosure SEC source: 0001415889-25-018316 · form4-06262025_110648.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,026,133 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.10 to $18.3795. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F3 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
June 24, 2025 Filed Jun 26, 2025 23:41 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	2,520	$18.43	$46,454.44	Disclosure SEC source: 0001415889-25-018316 · form4-06262025_110648.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,024,873 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.305 to $18.63. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: The total number of shares beneficially owned includes an additional incremental purchase of 200 shares on March 26, 2025, which was inadvertently omitted from the Form 4 filed on March 28, 2025 F3 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:42 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	8,584	$19.50	$167,381.13	Disclosure SEC source: 0001415889-25-017693 · form4-06182025_080636.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,022,153 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.20 to $19.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:56 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0000950170-25-082454 · ownership.xml · derivative · entry 6 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-02 F6 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the firstanniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vestingdate. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:56 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	10,500	$0.00	$0.00	Disclosure SEC source: 0000950170-25-082454 · ownership.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,596 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
May 21, 2025 Filed May 23, 2025 20:06 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	3,780	$3.86	$14,609.32	Disclosure SEC source: 0001415889-25-014428 · form4-05232025_080527.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 59,403 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
May 14, 2025 Filed May 15, 2025 20:17 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	6,300	$3.32	$20,919.15	Disclosure SEC source: 0001415889-25-013134 · form4-05152025_080534.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 55,623 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.215 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
May 13, 2025 Filed May 15, 2025 20:17 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	1,120	$3.16	$3,543.34	Disclosure SEC source: 0001415889-25-013134 · form4-05152025_080534.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 49,323 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.045 to $3.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
May 12, 2025 Filed May 13, 2025 20:13 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	12,601	$3.04	$38,300.74	Disclosure SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 3 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 48,203 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.825 to $3.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4 F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
May 09, 2025 Filed May 13, 2025 20:13 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	2,226	$3.62	$8,053.00	Disclosure SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 35,602 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
May 09, 2025 Filed May 13, 2025 20:13 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	33,376	$3.19	$106,562.89	Disclosure SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 33,376 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $3.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
March 26, 2025 Filed Mar 28, 2025 21:36 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	1,135	$22.49	$25,520.59	Disclosure SEC source: 0001415889-25-009198 · form4-03282025_090345.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,013,569 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.37 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
March 04, 2025 Filed Mar 6, 2025 22:32 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	4,005	$21.02	$84,203.12	Disclosure SEC source: 0001415889-25-007263 · form4-03062025_100302.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,012,434 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.545 to $21.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:11 UTC	MBX Biosciences, Inc. MBX · Entity 4247	ConversionSeries B Convertible Preferred Stock · Derivative	28,297,265	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-107536 · ownership.xml · derivative · entry 4 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,353,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.direct: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:11 UTC	MBX Biosciences, Inc. MBX · Entity 4247	ConversionSeries A Convertible Preferred Stock · Derivative	18,922,852	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-107536 · ownership.xml · derivative · entry 3 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,574,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.direct: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:11 UTC	MBX Biosciences, Inc. MBX · Entity 4247	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000950170-24-107536 · ownership.xml · nonDerivative · entry 2 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,552,774 F3 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.direct: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:11 UTC	MBX Biosciences, Inc. MBX · Entity 4247	ConversionCommon Stock	3,927,774	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-107536 · ownership.xml · nonDerivative · entry 1 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,927,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.direct: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
May 23, 2024 Filed May 24, 2024 23:47 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $10.30	$0.00	Disclosure SEC source: 0000950170-24-064842 · ownership.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-22 F5 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
May 23, 2024 Filed May 24, 2024 23:47 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	10,500	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064842 · ownership.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,096 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	17,500	Not disclosed Strike: $19.00	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 8 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	10,000	Not disclosed Strike: $7.43	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 7 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	10,000	Not disclosed Strike: $13.89	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 6 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	7,650	Not disclosed Strike: $13.45	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2031-01-03 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	7,650	Not disclosed Strike: $3.62	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 4 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2030-01-01 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	7,650	Not disclosed Strike: $4.09	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 3 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2029-01-01 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	7,650	Not disclosed Strike: $11.31	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · derivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2028-01-01 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7 · price: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 18, 2024 Filed May 21, 2024 00:10 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	OtherCommon Stock	2,829,347	Not disclosed	Not disclosed	Disclosure SEC source: 0001626199-24-000097 · wk-form4_1716250233.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences VIII, L.P. Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. Read SEC document
April 25, 2024 Filed Apr 29, 2024 20:32 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	OtherWarrant (Right to Buy) · Derivative	1,200,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-24-011664 · form4-04292024_080401.xml · derivative · entry 3 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: Frazier Life Sciences VIII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,200,000 shares Expires not disclosed F3 · derivative.exercise_date: The warrant had no expiration date and was exercisable immediately. F3 · derivative.expiration_date: The warrant had no expiration date and was exercisable immediately. F1 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. Read SEC document
April 25, 2024 Filed Apr 29, 2024 20:32 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	19	$64.57	$1,226.83	Disclosure SEC source: 0001415889-24-011664 · form4-04292024_080401.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: Frazier Life Sciences VIII, L.P. Disclosed balance after: 2,829,347 F2 · kind: On April 25, 2024, Frazier Life Sciences VIII, L.P. exercised a warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share. Frazier Life Sciences VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 19 shares of Common Stock to pay the exercise price and issuing Frazier Life Sciences VIII, L.P. the remaining 1,199,981 shares of Common Stock. F1 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. Read SEC document
April 25, 2024 Filed Apr 29, 2024 20:32 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	OtherCommon Stock	1,200,000	$0.00	$1,200.00	Disclosure SEC source: 0001415889-24-011664 · form4-04292024_080401.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: Frazier Life Sciences VIII, L.P. Disclosed balance after: 2,829,366 F1 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. Read SEC document
April 04, 2024 Filed Apr 8, 2024 20:22 UTC	HilleVax, Inc. HLVX · Entity 75097	PurchaseCommon Stock	8,850	$14.50	$128,325.00	Disclosure SEC source: 0001415889-24-010490 · form4-04082024_080405.xml · nonDerivative · entry 1 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,544,187 F1 · ownership.direct: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
March 26, 2024 Filed Mar 28, 2024 20:30 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	8,429	$21.50	$181,223.50	Disclosure SEC source: 0001415889-24-009330 · form4-03282024_080315.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,008,429 F1 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
January 02, 2024 Filed Jan 5, 2024 00:03 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	17,500	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001626199-24-000011 · wk-form4_1704413025.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
December 11, 2023 Filed Dec 13, 2023 22:30 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	OtherWarrant (Right to Buy) · Derivative	145,251	$0.00 Strike: $12.74	$0.00	Disclosure SEC source: 0001209191-23-058530 · doc4.xml · derivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,251 shares Expires 2024-01-18 Read SEC document
December 11, 2023 Filed Dec 13, 2023 22:30 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	OtherCommon Stock	145,251	$12.74	$1,850,497.74	Disclosure SEC source: 0001209191-23-058530 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: Frazier Life Sciences VIII, L.P. Disclosed balance after: 1,629,366 F1 · ownership.nature: The shares of Common Stock are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any. Read SEC document
October 24, 2023 Filed Oct 26, 2023 20:09 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	PurchaseCommon Stock	80,000	$2.50	$200,000.00	Disclosure SEC source: 0001209191-23-053662 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764,232 Read SEC document
May 25, 2023 Filed May 30, 2023 23:03 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $11.72	$0.00	Disclosure SEC source: 0001209191-23-033025 · doc4.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F5 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
May 25, 2023 Filed May 30, 2023 23:03 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033025 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,596 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
January 06, 2023 Filed Jan 11, 2023 00:13 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantRestricted Stock Unit · Derivative	3,900	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002887 · doc4.xml · derivative · entry 2 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 06, 2023 Filed Jan 11, 2023 00:13 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantStock Option (right to buy) · Derivative	10,600	$0.00 Strike: $23.23	$0.00	Disclosure SEC source: 0001209191-23-002887 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 03, 2023 Filed Jan 6, 2023 00:00 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	10,000	$0.00 Strike: $7.43	$0.00	Disclosure SEC source: 0001626199-23-000020 · wf-form4_167296318497904.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
September 22, 2022 Filed Sep 26, 2022 20:09 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy · Derivative	20,000	$0.00 Strike: $10.02	$0.00	Disclosure SEC source: 0001209191-22-051239 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-21 F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on September 22, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following two years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document
August 05, 2022 Filed Aug 9, 2022 20:34 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	PurchaseCommon Stock	250,000	$20.00	$5,000,000.00	Disclosure SEC source: 0001209191-22-045014 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,684,232 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.